BNP Paribas Financial Markets Sells 7,286 Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST)

BNP Paribas Financial Markets cut its stake in Aquestive Therapeutics, Inc. (NASDAQ:AQST) by 38.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 11,540 shares of the company’s stock after selling 7,286 shares during the quarter. BNP Paribas Financial Markets’ holdings in Aquestive Therapeutics were worth $41,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Raymond James Financial Inc. bought a new position in shares of Aquestive Therapeutics in the fourth quarter valued at about $498,000. Harvey Capital Management Inc. raised its position in shares of Aquestive Therapeutics by 1,419.3% in the fourth quarter. Harvey Capital Management Inc. now owns 267,390 shares of the company’s stock valued at $952,000 after purchasing an additional 249,790 shares during the period. Vanguard Group Inc. raised its position in shares of Aquestive Therapeutics by 1.9% in the fourth quarter. Vanguard Group Inc. now owns 4,346,754 shares of the company’s stock valued at $15,474,000 after purchasing an additional 82,958 shares during the period. Renaissance Technologies LLC raised its position in shares of Aquestive Therapeutics by 233.6% in the fourth quarter. Renaissance Technologies LLC now owns 95,400 shares of the company’s stock valued at $340,000 after purchasing an additional 66,800 shares during the period. Finally, SG Americas Securities LLC raised its position in shares of Aquestive Therapeutics by 28.7% in the fourth quarter. SG Americas Securities LLC now owns 32,966 shares of the company’s stock valued at $117,000 after purchasing an additional 7,347 shares during the period. 32.45% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the stock. Alliance Global Partners reissued a “buy” rating on shares of Aquestive Therapeutics in a research report on Friday, March 7th. Oppenheimer assumed coverage on shares of Aquestive Therapeutics in a research note on Monday. They issued an “outperform” rating and a $7.00 price target on the stock. Lake Street Capital decreased their price target on shares of Aquestive Therapeutics from $10.00 to $8.00 and set a “buy” rating on the stock in a research note on Friday, March 7th. Raymond James set a $7.00 price target on shares of Aquestive Therapeutics in a research note on Friday, March 7th. Finally, HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Aquestive Therapeutics in a research note on Thursday, May 15th. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, Aquestive Therapeutics has an average rating of “Buy” and a consensus price target of $10.14.

Aquestive Therapeutics Stock Performance

AQST stock opened at $3.18 on Wednesday. The company’s 50-day simple moving average is $2.65 and its 200 day simple moving average is $3.15. Aquestive Therapeutics, Inc. has a 52 week low of $2.12 and a 52 week high of $5.80. The company has a market capitalization of $315.86 million, a PE ratio of -7.07 and a beta of 2.02.

Aquestive Therapeutics (NASDAQ:AQST) last released its quarterly earnings results on Monday, May 12th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.07). The company had revenue of $8.72 million for the quarter, compared to analyst estimates of $12.23 million. On average, analysts forecast that Aquestive Therapeutics, Inc. will post -0.46 EPS for the current year.

Aquestive Therapeutics Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.